Comments

Acumen Pharmaceuticals

ABOSNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$3.48
0.072.05%
At Close: -
$3.51
0.030.85%
After Hours: 6:59 PM EDT
15 minutes delayed
Acumen Pharmaceuticals (ABOS) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$22.00
Lowest Price Target1
$7.00
Consensus Price Target1
$13.14

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Acumen Pharmaceuticals (NASDAQ:ABOS) Stock, Analyst Ratings, Price Targets, Forecasts

Acumen Pharmaceuticals Inc has a consensus price target of $13.14 based on the ratings of 7 analysts. The high is $22 issued by BTIG on October 5, 2022. The low is $7 issued by Citigroup on July 25, 2024. The 3 most-recent analyst ratings were released by Citigroup, HC Wainwright & Co., and HC Wainwright & Co. on July 25, 2024, May 15, 2024, and March 27, 2024, respectively. With an average price target of $12.33 between Citigroup, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 251.41% upside for Acumen Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Mar
0
0
0
0
May
0
0
0
0
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Citigroup
HC Wainwright & Co.
Deutsche Bank
Credit Suisse
B of A Securities

1calculated from analyst ratings

Analyst Ratings for Acumen Pharmaceuticals

Buy NowGet Alert
07/25/2024Buy Now99.45%Citigroup
David Hoang
 → $7Initiates → BuyGet Alert
05/15/2024Buy Now327.39%HC Wainwright & Co.
Andrew Fein
 → $15ReiteratesBuy → BuyGet Alert
03/27/2024Buy Now327.39%HC Wainwright & Co.
Andrew Fein
$15 → $15MaintainsBuyGet Alert
12/12/2023Buy Now127.94%Deutsche Bank
Neena Bitritto-Garg
 → $8Initiates → BuyGet Alert
08/09/2023Buy Now270.4%Credit Suisse
Judah Frommer
 → $13ReiteratesOutperform → OutperformGet Alert
08/09/2023Buy Now327.39%HC Wainwright & Co.
Andrew Fein
 → $15ReiteratesBuy → BuyGet Alert
07/20/2023Buy Now298.89%B of A Securities
Geoff Meacham
 → $14Reinstates → BuyGet Alert
07/17/2023Buy Now270.4%Cantor Fitzgerald
Pete Stavropoulos
 → $13ReiteratesOverweight → OverweightGet Alert
07/17/2023Buy Now327.39%HC Wainwright & Co.
Andrew Fein
 → $15ReiteratesBuy → BuyGet Alert
05/18/2023Buy Now270.4%Cantor Fitzgerald
Pete Stavropoulos
 → $13Initiates → OverweightGet Alert
03/28/2023Buy Now270.4%Credit Suisse
Judah Frommer
$16 → $13MaintainsOutperformGet Alert
03/28/2023Buy Now327.39%HC Wainwright & Co.
Andrew Fein
 → $15Reiterates → BuyGet Alert
02/02/2023Buy Now327.39%HC Wainwright & Co.
Andrew Fein
 → $15Reiterates → BuyGet Alert
11/15/2022Buy Now355.88%Credit Suisse
Judah Frommer
$17 → $16MaintainsOutperformGet Alert
10/05/2022Buy Now526.83%BTIG
Thomas Shrader
$15 → $22MaintainsBuyGet Alert
07/15/2022Buy Now327.39%BTIG
Thomas Shrader
 → $15Initiates → BuyGet Alert
06/30/2022Buy Now327.39%HC Wainwright & Co.
Andrew Fein
 → $15Initiates → BuyGet Alert
03/29/2022Buy Now384.37%Credit Suisse
Judah Frommer
$26 → $17MaintainsOutperformGet Alert
01/21/2022Buy Now298.89%B of A Securities
Geoff Meacham
$16 → $14UpgradeNeutral → BuyGet Alert

FAQ

Q

What is the target price for Acumen Pharmaceuticals (ABOS) stock?

A

The latest price target for Acumen Pharmaceuticals (NASDAQ:ABOS) was reported by Citigroup on July 25, 2024. The analyst firm set a price target for $7.00 expecting ABOS to rise to within 12 months (a possible 99.45% upside). 6 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Acumen Pharmaceuticals (ABOS)?

A

The latest analyst rating for Acumen Pharmaceuticals (NASDAQ:ABOS) was provided by Citigroup, and Acumen Pharmaceuticals initiated their buy rating.

Q

When was the last upgrade for Acumen Pharmaceuticals (ABOS)?

A

The last upgrade for Acumen Pharmaceuticals Inc happened on January 21, 2022 when B of A Securities raised their price target to $14. B of A Securities previously had a neutral for Acumen Pharmaceuticals Inc.

Q

When was the last downgrade for Acumen Pharmaceuticals (ABOS)?

A

There is no last downgrade for Acumen Pharmaceuticals.

Q

When is the next analyst rating going to be posted or updated for Acumen Pharmaceuticals (ABOS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acumen Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acumen Pharmaceuticals was filed on July 25, 2024 so you should expect the next rating to be made available sometime around July 25, 2025.

Q

Is the Analyst Rating Acumen Pharmaceuticals (ABOS) correct?

A

While ratings are subjective and will change, the latest Acumen Pharmaceuticals (ABOS) rating was a initiated with a price target of $0.00 to $7.00. The current price Acumen Pharmaceuticals (ABOS) is trading at is $3.51, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch